New Lyme Disease Guidelines Welcomed by Sufferers of Chronic Lyme Disease
Current treatments for Lyme disease, particularly chronic forms of the disease, are inadequate, according to a new treatment guideline written by a group of leading experts.
Adopted by the International Lyme and Associated Disease Society (ILADS) and published in the Expert Review of Anti-infective Therapy, the guideline also proposes revamped treatment guidelines to help clinicians across the globe deliver better care to patients.
Lyme disease is a bacterial infection caused by infected ticks, and is thought to affect 300,000 people annually in the US alone. The chronic form of the disease, which sees long-lasting symptoms including fatigue, headaches and joint pain, is regularly misdiagnosed and mismanaged by clinicians.
The paper claims that current antibiotic protocols used by many physicians to prevent and treat Lyme disease are ineffective, and can actually lead to an increased risk of Lyme disease developing into a chronic illness.
Daniel Cameron MD, lead author of the study said: “We are seeing more people diagnosed with Lyme disease who simply don’t get better after being treated. Our goal with these new guidelines is to provide evidence-based, patient-centred care for sufferers, helping clinicians make the right treatment decisions.
“We strongly recommend that patient goals and values regarding treatment options be identified and considered during a shared decision-making process.”
The paper also notes the desperate need for better understanding of this complex illness. Currently there is limited available evidence regarding treatment.
Cameron continued: “The lack of pharmaceutical interest in Lyme disease and its concomitant funding has led to therapeutic innovation coming from clinicians. But we unquestionably need more research to better define the disease process and to establish highly effective therapeutic regimens.”
View the full journal article here.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance